ARTICLE | Company News

Endo, Mylan neurology news

February 3, 2014 8:00 AM UTC

The U.S. District Court for the District of Delaware ruled that Patent No. 5,464,864 from Endo - formerly Endo Pharmaceuticals Holdings Inc. - is valid, and that an ANDA from Mylan for a generic version of migraine drug Frova frovatriptan infringes on the patent. Endo said the decision prevents Mylan from marketing its generic Frova in the U.S. before the '864 patent expiration on Nov. 8. The patent covers the use of tetrahydrocarbazole derivatives as serotonin (5-HT1) receptor agonists. The court dismissed Endo's claims in Endo Pharmaceuticals Inc. v. Mylan Pharmaceuticals Inc. et al. that Mylan's generic infringed on U.S. Patent Nos. 5,637,611 and 5,827,872 after Endo waived the claims during the trial. Endo filed suit in the court in August 2011. Frova is a selective serotonin (5-HT1B) receptor and serotonin (5-HT1D) receptor agonist (see BioCentury, Aug. 22, 2011). ...